Syndax Pharmaceuticals, Inc. SNDX · Stock Open Syndax Pharmaceuticals, Inc. in new tab
Syndax Pharmaceuticals, Inc. Analysis (SNDX)
Is Syndax Pharmaceuticals, Inc. a good investment? Syndax Pharmaceuticals, Inc. (SNDX) is currently trading at 18.07 USD. Market analysts have a consensus price target of 37.55 USD. This suggests a potential upside from current levels.
Earnings Schedule: Syndax Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 2, 2026. The market consensus estimate for Forward EPS is -0.82.
Investor FAQ
Does Syndax Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Syndax Pharmaceuticals, Inc.?
Syndax Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 2, 2026. The company currently has a trailing EPS of -2.51.
Company Profile
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Community Discussion